イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - omeprazolo - omeprazolo - 343 mg - omeprazole

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - ialuronato sodico - ialuronato sodico - 17 milligrammo (i), ialuronato sodico - 17 mg - hyaluronic acid

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - formosulfatiazolo - formosulfatiazolo - 7.5 grammo (i), formosulfatiazolo - 7.5 g, formosulfatiazolo - nd, formosulfatiazolo - 50 g - formosulfathiazole

イタリア - イタリア語 - Ministero della Salute

ceva salute animale s.p.a. - miconazolo - miconazolo - 100 mg - miconazole

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - fenilbutazone - fenilbutazone - 8 grammo (i), fenilbutazone sodico - 20 grammo (i) ; fenilbutazone - nd, fenilbutazone sodico - nd ; fenilbutazone - 2 grammo (i), fenilbutazone sodico - nd ; fenilbutazone - 8 g, fenilbutazone - 2 g; fenilbutazone sodico - nd, fenilbutazone - nd ; fenilbutazone sodico - 20 g, fenilbutazone sodico - nd ; fenilbutazone - 2 g - phenylbutazone

イタリア - イタリア語 - Ministero della Salute

acme drugs s.r.l. - nicarbazina - nicarbazina - 0.08 g - nicarbazine

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - ivermectina - ivermectina - 1.87 grammo (i), ivermectina - 1.87 g - ivermectin

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - butorfanolo tartrato - butorfanolo tartrato - 14.58 milligrammo (i), butorfanolo tartrato - 14.58 mg - butorphanol

イタリア - イタリア語 - Ministero della Salute

acme s.r.l. - acetilcisteina - acetilcisteina - 1 g - acetylcysteine

欧州連合 - イタリア語 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosoppressori - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.